company background image
VETO

Vetoquinol ENXTPA:VETO Stock Report

Last Price

€125.00

Market Cap

€1.5b

7D

-1.4%

1Y

18.1%

Updated

28 May, 2022

Data

Company Financials +
VETO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance5/6
Financial Health6/6
Dividends0/6

VETO Stock Overview

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region.

Vetoquinol Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vetoquinol
Historical stock prices
Current Share Price€125.00
52 Week High€161.00
52 Week Low€100.40
Beta0.66
1 Month Change-0.16%
3 Month Change-7.27%
1 Year Change18.15%
3 Year Change131.48%
5 Year Change145.10%
Change since IPO443.48%

Recent News & Updates

May 07
Vetoquinol SA (EPA:VETO) Shares Could Be 29% Below Their Intrinsic Value Estimate

Vetoquinol SA (EPA:VETO) Shares Could Be 29% Below Their Intrinsic Value Estimate

In this article we are going to estimate the intrinsic value of Vetoquinol SA ( EPA:VETO ) by taking the expected...

Apr 06
I Ran A Stock Scan For Earnings Growth And Vetoquinol (EPA:VETO) Passed With Ease

I Ran A Stock Scan For Earnings Growth And Vetoquinol (EPA:VETO) Passed With Ease

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...

Shareholder Returns

VETOFR PharmaceuticalsFR Market
7D-1.4%0.2%3.7%
1Y18.1%16.4%-3.7%

Return vs Industry: VETO exceeded the French Pharmaceuticals industry which returned 16.4% over the past year.

Return vs Market: VETO exceeded the French Market which returned -3.7% over the past year.

Price Volatility

Is VETO's price volatile compared to industry and market?
VETO volatility
VETO Average Weekly Movement5.5%
Pharmaceuticals Industry Average Movement5.2%
Market Average Movement5.9%
10% most volatile stocks in FR Market10.0%
10% least volatile stocks in FR Market3.4%

Stable Share Price: VETO is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: VETO's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19332,396Matthieu Frechinhttps://www.vetoquinol.com

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, and dogs. The company was founded in 1933 and is headquartered in Lure, France.

Vetoquinol Fundamentals Summary

How do Vetoquinol's earnings and revenue compare to its market cap?
VETO fundamental statistics
Market Cap€1.48b
Earnings (TTM)€62.86m
Revenue (TTM)€521.27m

23.5x

P/E Ratio

2.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VETO income statement (TTM)
Revenue€521.27m
Cost of Revenue€228.63m
Gross Profit€292.65m
Other Expenses€229.78m
Earnings€62.86m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Sep 15, 2022

Earnings per share (EPS)5.31
Gross Margin56.14%
Net Profit Margin12.06%
Debt/Equity Ratio0.9%

How did VETO perform over the long term?

See historical performance and comparison

Dividends

0.6%

Current Dividend Yield

15%

Payout Ratio

Does VETO pay a reliable dividends?

See VETO dividend history and benchmarks
When do you need to buy VETO by to receive an upcoming dividend?
Vetoquinol dividend dates
Ex Dividend DateJun 03 2022
Dividend Pay DateJun 07 2022
Days until Ex dividend5 days
Days until Dividend pay date9 days

Does VETO pay a reliable dividends?

See VETO dividend history and benchmarks

Valuation

Is Vetoquinol undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


25.4%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: VETO (€125) is trading below our estimate of fair value (€167.51)

Significantly Below Fair Value: VETO is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: VETO's Price-To-Earnings Ratio (23.5x) is in line with the French Pharmaceuticals industry average.

PE vs Market: VETO is poor value based on its Price-To-Earnings Ratio (23.5x) compared to the French market (16.2x).


Price to Earnings Growth Ratio

PEG Ratio: VETO is poor value based on its PEG Ratio (5.7x)


Price to Book Ratio

PB vs Industry: VETO is overvalued based on its Price-To-Book Ratio (3.4x) compared to the FR Pharmaceuticals industry average (2.4x).


Future Growth

How is Vetoquinol forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


4.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VETO's forecast earnings growth (4.2% per year) is above the savings rate (0.3%).

Earnings vs Market: VETO's earnings (4.2% per year) are forecast to grow slower than the French market (11.9% per year).

High Growth Earnings: VETO's earnings are forecast to grow, but not significantly.

Revenue vs Market: VETO's revenue (5.2% per year) is forecast to grow slower than the French market (5.8% per year).

High Growth Revenue: VETO's revenue (5.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: VETO's Return on Equity is forecast to be low in 3 years time (14.4%).


Past Performance

How has Vetoquinol performed over the past 5 years?

Past Performance Score

5/6

Past Performance Score 5/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


6.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: VETO has high quality earnings.

Growing Profit Margin: VETO's current net profit margins (12.1%) are higher than last year (4.5%).


Past Earnings Growth Analysis

Earnings Trend: VETO's earnings have grown by 6.6% per year over the past 5 years.

Accelerating Growth: VETO's earnings growth over the past year (227%) exceeds its 5-year average (6.6% per year).

Earnings vs Industry: VETO earnings growth over the past year (227%) exceeded the Pharmaceuticals industry 9%.


Return on Equity

High ROE: VETO's Return on Equity (14.2%) is considered low.


Financial Health

How is Vetoquinol's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: VETO's short term assets (€273.7M) exceed its short term liabilities (€157.0M).

Long Term Liabilities: VETO's short term assets (€273.7M) exceed its long term liabilities (€26.2M).


Debt to Equity History and Analysis

Debt Level: VETO has more cash than its total debt.

Reducing Debt: VETO's debt to equity ratio has reduced from 7.7% to 0.9% over the past 5 years.

Debt Coverage: VETO's debt is well covered by operating cash flow (2183.4%).

Interest Coverage: VETO's interest payments on its debt are well covered by EBIT (325.7x coverage).


Balance Sheet


Dividend

What is Vetoquinol current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


0.64%

Current Dividend Yield

Upcoming Dividend Payment

TodayMay 29 2022Ex Dividend DateJun 03 2022Dividend Pay DateJun 07 20224 days from Ex DividendBuy in the next 5 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: VETO's dividend (0.64%) isn’t notable compared to the bottom 25% of dividend payers in the French market (1.68%).

High Dividend: VETO's dividend (0.64%) is low compared to the top 25% of dividend payers in the French market (4.89%).


Stability and Growth of Payments

Stable Dividend: VETO is not paying a notable dividend for the French market, therefore no need to check if payments are stable.

Growing Dividend: VETO is not paying a notable dividend for the French market, therefore no need to check if payments are increasing.


Earnings Payout to Shareholders

Earnings Coverage: VETO is not paying a notable dividend for the French market.


Cash Payout to Shareholders

Cash Flow Coverage: VETO is not paying a notable dividend for the French market.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

11.5yrs

Average management tenure


CEO

Matthieu Frechin (52 yo)

12.08yrs

Tenure

€472,029

Compensation

Mr. Matthieu Frechin has been the Chief Executive Officer at Vetoquinol SA (formerly known as Vétoquinol SA) since April 01, 2010. Mr. Frechin served as Deputy Chief Executive Officer of Vetoquinol SA (for...


CEO Compensation Analysis

Compensation vs Market: Matthieu's total compensation ($USD505.71K) is below average for companies of similar size in the French market ($USD935.39K).

Compensation vs Earnings: Matthieu's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: VETO's management team is seasoned and experienced (11.5 years average tenure).


Board Members

Experienced Board: VETO's board of directors are seasoned and experienced ( 10.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Vetoquinol SA's employee growth, exchange listings and data sources


Key Information

  • Name: Vetoquinol SA
  • Ticker: VETO
  • Exchange: ENXTPA
  • Founded: 1933
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: €1.479b
  • Shares outstanding: 11.83m
  • Website: https://www.vetoquinol.com

Number of Employees


Location

  • Vetoquinol SA
  • Magny-Vernois
  • 34 rue du chêne Sainte Anne
  • Lure
  • Franche Comté
  • 70204
  • France

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/28 00:00
End of Day Share Price2022/05/27 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.